Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy ImmunoGen stock (IMGN)

Buy ImmunoGen stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

ImmunoGen is a biotechnology business based in the US. ImmunoGen shares (IMGN) are listed on the NASDAQ and all prices are listed in US Dollars. ImmunoGen employs 277 staff and has a trailing 12-month revenue of around $287.6 million.

Our top picks for where to buy ImmunoGen stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Earn up to $300 with qualifying deposits
  • Discover new opportunities with Opto's AI-driven thematic investing system
  • Theme and ETF screener

Our pick for stock bonuses

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options with no options contract fees
  • Get up to $1,000 in stock when you fund a new account within 30 days
  • Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%

How to buy ImmunoGen stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – IMGN. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy ImmunoGen stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Product USFST Finder Score Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder score
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Finder score
Stocks, ETFs
$0
$0
N/A
Earn up to $300
Finder score
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Finder score
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
4.35%
Get up to $10,000 and transfer fees covered
loading

What is the Finder Score?

The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.

We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.

Read the full Finder Score breakdown

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

ImmunoGen stock price (NASDAQ: IMGN)

Use our graph to track the performance of IMGN stocks over time.

ImmunoGen shares at a glance

Information last updated 2024-04-21.
52-week range$29.15 - $31.25
50-day moving average $29.71
200-day moving average $19.72
Wall St. target price$25.50
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-0.28

Is it a good time to buy ImmunoGen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ImmunoGen financials

Revenue TTM $287.6 million
Operating margin TTM 22.88%
Gross profit TTM $-104,764,000
Return on assets TTM -8.49%
Return on equity TTM -19.88%
Profit margin -25.56%
Book value $2.11
Market Capitalization $8.7 billion

TTM: trailing 12 months

ImmunoGen share dividends

We're not expecting ImmunoGen to pay a dividend over the next 12 months.

ImmunoGen share price volatility

Over the last 12 months, ImmunoGen's shares have ranged in value from as little as $29.15 up to $31.25. A popular way to gauge a stock's volatility is its "beta".

IMGN.US volatility(beta: 1.17)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ImmunoGen's is 1.171. This would suggest that ImmunoGen's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

ImmunoGen overview

ImmunoGen, Inc. , a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc. ; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc. ; CytomX Therapeutics, Inc.

Frequently asked questions

null
What percentage of ImmunoGen is owned by insiders or institutions?
Currently 0.324% of ImmunoGen shares are held by insiders and 86.515% by institutions.
How many people work for ImmunoGen?
Latest data suggests 277 work at ImmunoGen.
When does the fiscal year end for ImmunoGen?
ImmunoGen's fiscal year ends in December.
Where is ImmunoGen based?
ImmunoGen's address is: 830 Winter Street, Waltham, MA, United States, 02451-1477
What is ImmunoGen's ISIN number?
ImmunoGen's international securities identification number is: US45253H1014
What is ImmunoGen's CUSIP number?
ImmunoGen's Committee on Uniform Securities Identification Procedures number is: 45253H101

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site